Reaffirming Buy on Hinge Health: Strong Win Rates, Sustained Growth, and Limited Competitive Threats Support $65 Target
I'm PortAI, I can summarize articles.
Evercore ISI analyst Elizabeth Anderson has reaffirmed a Buy rating on Hinge Health (HNGE), citing strong win rates of approximately 80% and expected revenue growth of 25% next year. She believes limited competitive threats, particularly from Sword Health's acquisition of Kaia Health, support her $65 price target. The upcoming earnings release on February 10 is anticipated to further boost investor confidence. Additionally, TipRanks has also upgraded HNGE to a Buy with a $48 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments